Behavioral and psychological symptoms and psychotropic drugs among people with cognitive impairment in nursing homes in 2007 and 2013
- 530 Downloads
The use of psychotropic drugs to treat behavioral and psychological symptoms among people with dementia has been widely questioned because of its limited efficacy and risk of harmful side-effects. The objectives of this study was to compare the prevalence of behavioral and psychological symptoms and the use of psychotropic drug treatments among old people with cognitive impairment living in geriatric care units in 2007 and 2013.
Two questionnaire surveys were performed in 2007 and 2013, comprising all those living in geriatric care units in the county of Västerbotten in northern Sweden. A comparison was made between 1971 people from 2007 and 1511 people from 2013. Data were collected concerning psychotropic and antidementia drug use, functioning in the activities of daily living (ADL), cognition, and behavioral and psychological symptoms, using the Multi-Dimensional Dementia Assessment Scale (MDDAS).
Between 2007 and 2013, the use of antipsychotic drugs declined from 25.4 to 18.9 %, and of anxiolytic, hypnotic, and sedative drugs from 35.5 to 29.4 %. The prevalence of people prescribed antidepressant drugs remained unchanged while antidementia drug prescription increased from 17.9 to 21.5 %. When controlled for demographic changes, 36 out of 39 behavioral and psychological symptoms showed no difference in prevalence between the years.
The use of antipsychotic, anxiolytic, hypnotic, and sedative drugs declined considerably between 2007 and 2013 among old people with cognitive impairment living in geriatric care units. Despite this reduction, the prevalences of behavioral and psychological symptoms remained largely unchanged.
KeywordsDementia Nursing home Behavioral and psychological symptoms Alzheimer’s disease Psychotropic drugs Antipsychotics
This study was supported financially by grants from the Swedish Dementia Association, County Council of Västerbotten, and Swedish Brainpower.
Description of authors’ roles
M. Gustafsson and H. Lövheim analyzed and interpreted the data and prepared the manuscript. P.O. Sandman, S. Karlsson, and U. Isaksson were responsible for the study concept, design, and acquisition of subjects. All authors carried out a critical revision of the manuscript, contributed with comments, and approved the final version.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest to disclose.
- 6.Hanlon JT, Horner RD, Schmader KE, Fillenbaum GG, Lewis IK, Wall WE Jr, Landerman LR, Pieper CF, Blazer DG, Cohen HJ (1998) Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther 64(6):684–692Google Scholar
- 8.Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O’Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378(9789):403–411CrossRefPubMedGoogle Scholar
- 12.Ballard C, Waite J (2006) The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev (1): Cd003476Google Scholar
- 13.Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, Christiaens T (2013) Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev 3: Cd007726Google Scholar
- 20.The National Board of Health and Welfare (2010) Indikatorer för utvärdering av kvaliteten i äldres läkemedelsterapi. [Eng. Indicators for evaluating the quality of older people’s drug therapy]. http://www.socialstyrelsen.se/publikationer2010/2010-6-29/. Accessed 1 September 2015
- 21.Medical products agency (2008) Läkemedelsverkets behandlingsrekommendationer: Läkemedelsbehandling och bemötande vid Beteendemässiga och Psykiska Symtom vid Demenssjukdom—BPSD. [Eng. Drug therapy and treatment for Behavioral and Psychological Symptoms of Dementia—BPSD]. http://www.lakemedelsverket.se/malgrupp/Halso—sjukvard/Behandlings–rekommendationer/Behandlingsrekommendation—listan/Beteendemassiga-och-psykiska-symtom-vid-demenssjukdom–BPSD/. Accessed 17 June 2015
- 22.EMA - European Medicines Agency (2010). http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500054057.pdf/. Accessed 4 September 2015
- 23.FDA—Food and Drug Administration (2008). http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm124830.htm/. Accessed 15 May 2015
- 24.Schulze J, van den Bussche H, Glaeske G, Kaduszkiewicz H, Wiese B, Hoffmann F (2013) Impact of safety warnings on antipsychotic prescriptions in dementia: nothing has changed but the years and the substances. In: Eur Neuropsychopharmacoled. 2013 Elsevier B.V. and ECNP, pp1034–1042Google Scholar
- 28.Porsteinsson AP, Drye LT, Pollock BG, Devan and DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG (2014) Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311(7):682–691CrossRefPubMedPubMedCentralGoogle Scholar